STRATA affirms its IP portfolio exclusivity in XTRAC, JAK inhibitor combo

STRATA Skin Sciences (SSKN) affirms its patent portfolio provides intellectual property, IP, and market exclusivity for combination therapies of its XTRAC excimer laser when used with JAK inhibitor, Systemic and Biologic drugs, bolstering new expansion opportunities as it pursues the inclusion of the expanded CPT codes including all inflammatory and autoimmune skin conditions into the CMS physician fee schedule as early as January 1, 2026. “It is important that we continue to grow our market by expanding into new indications, maximizing revenue opportunities for the Company and our partner clinics. Foundational to this long-term growth initiative are our prescient investments in our Intellectual Property and technology, ensuring broad protection and market exclusivity. These patents will play a significant role when encountering attempts by inferior technologies to try and capture some of the upcoming available market growth. We are steadfast in our commitment to leverage the therapeutic capabilities of our technology to expand clinical applications and demonstrate our dedication to patient care, good partnership, and shareholder value. As Strata is demonstrating in its defensive litigation with LaserOptek, the company anticipates very significant damages collected and a longer-term injunctive relief protecting the years of investment into market and intellectual property creation,” said Dr. Dolev Rafaeli, STRATA Skin Sciences President and CEO.